Procedures
toxicity, death
DISEASE PROGRESSION, DISEASE
BAT1706 or EU‐bevacizumab, plus paclitaxel and carboplatin, were given every 3 weeks (21 days) for up to six cycles of combination therapy. BAT1706 (15 mg/kg) or EU‐bevacizumab (15 mg/kg) were administered intravenously prior to paclitaxel and carboplatin, with the initial dose given over 90 min; if well‐tolerated, subsequent infusions were given over 60 min. Dose adjustments were not permitted. Paclitaxel was administered intravenously over 3 h (or according to the package insert) at an initial dose of 200 mg/mFor cycle 1, day 1, only BAT1706 or EU‐bevacizumab were given; on day 2, paclitaxel and carboplatin were administered. From cycle 2 (day 22) to cycle 6, BAT1706 or EU‐bevacizumab were administered first, followed by paclitaxel and then carboplatin on the same day. Any delay in chemotherapy necessitated a delay in BAT1706/EU‐bevacizumab administration, and vice versa, during the combination treatment.After six cycles of combination therapy, all patients with complete response (CR), partial response (PR), or stable disease received maintenance therapy with BAT1706 or EU‐bevacizumab for up to 12 months after week 18. Maintenance therapy was stopped if any of the following occurred: investigator‐assessed disease progression, excessive toxicity, investigator's judgment, withdrawal of consent, loss to follow‐up, death, start of a new anticancer therapy, or study termination by the Sponsor, whichever occurred first.After this 12‐month treatment period, patients still benefiting from treatment were able to enroll in a long‐term extension (LTE) study.